Startups

Sibylla Biotech
Bresso, Milan, Italy
Sibylla Biotech S.p.A. is an Italian preclinical drug-discovery company founded in2017 from interdisciplinary protein-folding research associated with Trento, Perugia, INFN and Telethon. Its PPI-FIT platform models transient protein-folding intermediates to identify small-molecule Fold Interfering Degraders. Its Oneiros platform explicitly applies machine learning to pocket discovery and molecular optimization. CNS discovery collaborations with Takeda and Ono are research partnerships; undisclosed commercial fees and milestones are not treated as equity funding or realized cash. Therapeutic effects remain investigational, without verified clinical approval or efficacy. Current own directory publishes35 distinct people across board, executives, computational science, medicinal chemistry, biology, business development and scientific founders. Exact legal footer identifies VAT/register04514620238 and Bresso laboratories; historical S.r.l. and current S.p.A. are the same source-qualified operating company. Nominal share capital EUR187758.17 is not counted as financing. Actual disclosed equity funding is EUR2.4M initial investment announced October14,2019 and EUR23M Series A closed October4,2022; the CEO’s EUR25.4M figure is cumulative, not a third round.
Founded 2017



































